Loading
A phase 3 trial of Camrelizumab and Rivoceranib (apatinib) in gastric & gastro-oesophageal junction cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC is a phase 3 interventional study registered as NCT04342910 by Jiangsu HengRui Medicine Co., Ltd., with 550 participants planned, started 2020-09-21 and due to reach its primary completion in 2026-04-01. Interventions recorded: camrelizumab, Apatinib Mesylate, Paclitaxel and Irinotecan.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Immune checkpoint inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors, Immune checkpoint inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy, Immune checkpoint inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Small-molecule kinase inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/